Anti-SNX19 monoclonal antibody

Pre-made anti-SNX19 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SNX19/SNX19 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1785-Ab-1/ GM-Tg-hg-IP1785-Ab-2Anti-Human SNX19 monoclonal antibodyHuman
GM-Tg-rg-IP1785-Ab-1/ GM-Tg-rg-IP1785-Ab-2Anti-Rat SNX19 monoclonal antibodyRat
GM-Tg-mg-IP1785-Ab-1/ GM-Tg-mg-IP1785-Ab-2Anti-Mouse SNX19 monoclonal antibodyMouse
GM-Tg-cynog-IP1785-Ab-1/ GM-Tg-cynog-IP1785-Ab-2Anti-Cynomolgus/ Rhesus macaque SNX19 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1785-Ab-1/ GM-Tg-felg-IP1785-Ab-2Anti-Feline SNX19 monoclonal antibodyFeline
GM-Tg-cang-IP1785-Ab-1/ GM-Tg-cang-IP1785-Ab-2Anti-Canine SNX19 monoclonal antibodyCanine
GM-Tg-bovg-IP1785-Ab-1/ GM-Tg-bovg-IP1785-Ab-2Anti-Bovine SNX19 monoclonal antibodyBovine
GM-Tg-equg-IP1785-Ab-1/ GM-Tg-equg-IP1785-Ab-2Anti-Equine SNX19 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1785-Ab-1/ GM-Tg-hg-IP1785-Ab-2; GM-Tg-rg-IP1785-Ab-1/ GM-Tg-rg-IP1785-Ab-2;
GM-Tg-mg-IP1785-Ab-1/ GM-Tg-mg-IP1785-Ab-2; GM-Tg-cynog-IP1785-Ab-1/ GM-Tg-cynog-IP1785-Ab-2;
GM-Tg-felg-IP1785-Ab-1/ GM-Tg-felg-IP1785-Ab-2; GM-Tg-cang-IP1785-Ab-1/ GM-Tg-cang-IP1785-Ab-2;
GM-Tg-bovg-IP1785-Ab-1/ GM-Tg-bovg-IP1785-Ab-2; GM-Tg-equg-IP1785-Ab-1/ GM-Tg-equg-IP1785-Ab-2
Products NameAnti-SNX19 monoclonal antibody
Formatmab
Target NameSNX19
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SNX19 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1785-Ag-1Recombinant multi-species SNX19/ CHET8 protein


    Target information

    Target IDGM-IP1785
    Target NameSNX19
    Gene ID399979,102607,315478,715704,119871776,101094128,504649,100072714
    Gene Symbol and Synonyms3526401K03Rik,CHET8,mKIAA0254,SNX19
    Uniprot AccessionQ92543
    Uniprot Entry NameSNX19_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000120451
    Target ClassificationN/A

    The target: SNX19, gene name: SNX19, also named as CHET8. Islet antigen-2 (IA-2) is an autoantigen in type 1 diabetes and plays a role in insulin secretion. IA-2 is found in dense-core secretory vesicles and interacts with the product of this gene, a sorting nexin. In mouse pancreatic beta-cells, the encoded protein influenced insulin secretion by stabilizing the number of dense-core secretory vesicles. [provided by RefSeq, Dec 2016].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.